CLAFORAN - PWS INJ 2.0G/VIAL POWDER FOR SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

اشتر الآن

خصائص المنتج خصائص المنتج (SPC)
13-11-2014

العنصر النشط:

CEFOTAXIME SODIUM

متاح من:

SANOFI-AVENTIS CANADA INC

ATC رمز:

J01DD01

INN (الاسم الدولي):

CEFOTAXIME

جرعة:

2G

الشكل الصيدلاني:

POWDER FOR SOLUTION

تركيب:

CEFOTAXIME SODIUM 2G

طريقة التعاطي:

INTRAMUSCULAR

الوحدات في الحزمة:

IM:6ML/IV:11ML/IV INF.:56ML TO 1011ML; 10X2G

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

THIRD GENERATION CEPHALOSPORINS

ملخص المنتج:

Active ingredient group (AIG) number: 0152507002; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2017-11-24

خصائص المنتج

                                PRODUCT MONOGRAPH
PR
CLAFORAN
®
Cefotaxime for injection, Mfr. Std.
1g and 2g cefotaxime (as cefotaxime sodium) per vial
β-lactam Antibiotic
sanofi-aventis Canada Inc.
2905 Place Louis-R-Renaud
Laval, Quebec H7V 0A3
Date of Revision:
November 12, 2014
Submission Control No.: 176886
s-a Version dated
2
PRODUCT MONOGRAPH
PR
CLAFORAN
®
Cefotaxime for injection, Mfr. Std.
1g and 2g cefotaxime (as cefotaxime sodium) per vial
β-lactam Antibiotic
ACTION AND CLINICAL PHARMACOLOGY
CLAFORAN (cefotaxime for injection) is a semi-synthetic,
2-aminothiazolyl cephalosporin
antibiotic for parenteral use. _In vitro _studies indicate that the
antibacterial action of CLAFORAN
results from inhibition of cell wall synthesis. It is stable against
the action of most β-lactamases.
INDICATIONS AND CLINICAL USE
TREATMENT
_ _
_ _
CLAFORAN (cefotaxime for injection) may be indicated for the treatment
of infections caused
by susceptible strains of the designated micro-organisms in the
diseases listed below.
LOWER RESPIRATORY TRACT INFECTIONS:
Pneumonia
and
lung
abscess
caused
by
_Streptococcus _
_pneumoniae_
(formerly
_Diplococcus_
_pneumoniae_), other streptococci (excluding enterococci, e.g. _S.
faecalis_),_ Staphylococcus_ _aureus_
(penicillinase
and
non-penicillinase
producing),_ _
_Escherichia _
_coli_,_ _
_Hemophilus _
_influenzae_,
(including ampicillin resistant strains) and unspecified _Klebsiella_
species.
URINARY TRACT INFECTIONS:
Caused by _Escherichia coli_, unspecified _Klebsiella_ species
(including _K. pneumoniae_),_ Proteus_
_mirabilis_, indole positive _ Proteus_, _ Serratia marcescens_ and _
Staphylococcus epidermidis_. Also,
uncomplicated gonorrhea caused by _N. gonorrhoeae_ including
penicillin resistant strains.
BACTEREMIA/SEPTICEMIA:
Caused by _Escherichia coli_, unspecified _Klebsiella_ strains and
_Serratia marcescens_.
SKIN INFECTIONS:
Caused
by
_Staphylococcus _
_aureus_
(penicillinase
and
non-penicillinase
producing),
_S. epidermidis_, group A streptococci, _ Escherichia coli_, _ Proteus
mirabilis_ and indole
                                
                                اقرأ الوثيقة كاملة
                                
                            

مستندات بلغات أخرى

خصائص المنتج خصائص المنتج الفرنسية 12-11-2014

تنبيهات البحث المتعلقة بهذا المنتج